CommercialCoverageMedium impact
Noninvasive Fetal RHD Genotyping Using Cell-Free Fetal DNA (2.04.108)
Blue Shield of California·CA · OB-GYN, Genetics·Medical Policy
Effective date
Apr 1, 2026
We identified it
Apr 1, 2026
Summary
Blue Shield of California updated their policy for noninvasive fetal RHD genotyping using cell-free DNA, clarifying coverage criteria and removing the discontinued SensiGene test from consideration. The policy covers testing when pregnancy is at risk for alloimmunization, paternal typing is unavailable/heterozygous, and amniocentesis is declined/contraindicated.
Action Required
Before April 1, 2026: Review current billing practices for noninvasive fetal RHD genotyping to ensure claims meet the three required criteria (maternal RhD negative status or antibodies present, paternal antigen typing unavailable/heterozygous, amniocentesis declined/contraindicated). Update prior authorization workflows to verify these criteria are documented. Stop referencing SensiGene test as it's no longer available.